Baptist Health Cancer Care

Manmeet Ahluwalia, MD, discusses what early results from the CRUX trial of ruxolitinib for the treatment of patients with newly-diagnosed high-grade gliomas may mean for future research.

Results from the phase 1 EQUILIBRIUM study signal better outcomes for patients with newly diagnosed, MGMT methylated glioblastoma.

In an interview with Targeted Oncology, Rohan Garje, MD, discussed current treatment options for patients with prostate cancer and the role of PARP inhibitors.

The rapid progress in oncology, along with complex cases and rising costs, presents challenges in delivering high-quality cancer care.

In an interview with Targeted Oncology, Rupesh Kotecha, MD, discusses the background of this phase 1 study and current options for patients with brain metastases.

In the first comprehensive study of patients with pancreatic cancer treated with either MRI-guided radiotherapy or CT-guided radiotherapy, experts state MRI-guided treatment may be safer.

A prospective, multicenter trial continues to recruit patients with brain metastases to evaluate the real-world and patient-reported outcomes of surgically targeted radiation therapy.

During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, discussed with other physicians their experience with elacestrant in patients with estrogen receptor–positive, HER2-negative breast cancer. This is the second article based on this event.

Liquid biopsy is offering a noninvasive, real-time, and personalized approach to tumor assessment, and is already revolutionizing the field of clinical oncology.

For World Lymphoma Awareness Day, Yuliya P.L. Linhares, MD, discusses how novel therapies are changing the approach to treatment for this patient population.

Fertility preservation should be offered to anyone who is interested in becoming pregnant after chemotherapy for breast cancer.

Manmeet Ahluwalia, MD, discusses brain metastases in patient with biomarker-driven lung cancer and outcomes of these patients.

During an interview with Targeted Oncology, Geoffrey Young, MD, PhD, discussed the impact of molecular testing, targeted therapies, and new approaches to surgical management of thyroid cancers.

Rohan Garje, MD, explains some of the differences between the sarcomatoid and classic carcinoma of the bladder.

In season 4, episode 12 of Targeted Talks, Federico Albrecht, MD, gives and account of 2 cases of patients with small cell lung cancer and how these patients were treated.

An era of advanced molecular testing and personalized medicine has allowed for the de-escalation of breast cancer treatment for many patients. This is part 1 of a 2-part series on overtreatment of breast cancer.

Federico Albrecht, MD, comments on clinical trials supporting the use of PD-L1 inhibitor therapy in combination with standard chemotherapy for the treatment of patients with extensive-stage small cell lung cancer.

John Diaz, MD, discusses some known biomarkers in ovarian cancer and where he hopes to see more research in the future.

George Nahas, DO, discusses ongoing research that may shape the future treatment landscape of multiple myeloma.

In an interview with Targeted Oncology, Antonio Ucar, MD, discussed the evolving role of sunitinib for the second-line treatment of gastrointestinal stromal tumors, and the Peak study.

Investigators are evaluating the efficacy and safety of selinexor vs placebo when used as a maintenance therapy for patients with p53 wild-type advanced or recurrent endometrial cancer.

Results from a subgroup analysis of the phase 3 SIENDO study show a survival advantage, signaling that tp53 may have predictive value for treatment with selinexor, in addition to its prognostic value.

John Diaz, MD, discusses potential innovations for the ovarian cancer space.

In an interview, Rohan Garje, MD, discussed his research on comparing the outcomes of sarcomatoid and classic urothelial carcinoma of bladder.

In an interview with Targeted Oncology, Ahmad Ozair, MBBS, discussed treatments for glioblastoma and a trial evaluating surgically targeted radiation therapy in this patient population.

In an interview with Targeted Oncology, Manmeet S. Ahluwalia, MD, a Q2 2023 Oncology Icons honoree, looks back on the career moves that led him to this award, including his work at Cleveland Clinic, the ASCO Leadership Development Program, and Baptist Health South Florida.

George Nahas, DO, discusses recent and ongoing research that has impacted the current treatment landscape for patients with multiple myeloma.

In an interview with Targeted Oncology, George Nahas, DO, discussed relevant research on chimeric antigen receptor therapy, bispecifics, and more that are moving the needle in multiple myeloma research.

Rohan Garje, MD, discusses the goals of his research in assessing the outcomes of sarcomatoid vs classic urothelial carcinoma of bladder.

Manmeet Ahluwalia, MD, discusses results from the CRUX trial which were presented during the 2023 American Society of Clinical Oncology Annual Meeting.